Toronto, Ontario – November 26, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has commenced launch of its next generation therapeutic laser, the TLC-2000 Therapeutic Medical Laser System, in the United States.
The United States market represents over 1.3 million practitioners with the ability to purchase the TLC-2000 Therapeutic Medical Laser System for their clinical practices.
David Smith, Director of Global Sales stated, “The FDA approval of the TLC-2000 represents a watershed moment for the Company to dramatically increase its customer base in the US and significantly increase corporate revenue through the sale of the safest and most effective therapeutic laser system ever designed to the largest consumer market in the world. I look forward to building the high performing team that will ultimately lead to these significant revenues for Theralase in 2016 and beyond.”
Roger Dumoulin-White, President and CEO, Theralase stated that, “Theralase has now gained access to the largest consumer market in the world with a technology that is far superior to competitive products in safety, but more importantly in efficacy. I look forward to welcoming the world to the next generation of therapeutic laser technology. The United States remains the largest medical device market in the world with a market size of approximately $110 billion, expected to reach $133 billion by 2016.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com